Literature DB >> 12563538

Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication: a review.

Hannu Koponen1, Kaisa Saari, Markku Savolainen, Matti Isohanni.   

Abstract

Antipsychotic medication is the mainstay of treatment for functional psychotic illnesses. However, for some patients weight gain and the disturbances in blood-lipid levels and glucose balance associated with their use are significant disadvantages, and pose health risks that may affect prognosis. A substantial body of evidence suggests that weight gain is at least partly related to the blocking effects of antipsychotic medication on serotonin- and histamine-mediated neurotransmission. The disadvantages associated with weight gain can be reduced by an appropriate choice of antipsychotic and avoidance of polypharmacy, by regular monitoring of the patient's weight, and, if necessary, by the patient's participation in a dieting programme.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12563538     DOI: 10.1007/s00406-002-0394-1

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  6 in total

1.  The QTc interval and its dispersion in patients receiving two atypical antipsychotics.

Authors:  Christoph U Correll; Anne M Frederickson; Vicki Figen; Elizabeth J Ginn-Scott; Rudy A Pantaleon Moya; John M Kane; Peter Manu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06-20       Impact factor: 5.270

2.  Serum lipid levels in seasonal affective disorder.

Authors:  Edda Pjrek; Dietmar Winkler; David W Abramson; Anastasios Konstantinidis; Jürgen Stastny; Matthäus Willeit; Nicole Praschak-Rieder; Siegfried Kasper
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-12-05       Impact factor: 5.270

3.  Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey.

Authors:  Jaana Suvisaari; Jonna Perälä; Samuli I Saarni; Tommi Härkänen; Sami Pirkola; Matti Joukamaa; Seppo Koskinen; Jouko Lönnqvist; Antti Reunanen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04       Impact factor: 5.270

Review 4.  The German Research Network on Schizophrenia--impact on the management of schizophrenia.

Authors:  Wolfgang Wölwer; Anja Baumann; Andreas Bechdolf; Gerhard Buchkremer; Heinz Häfner; Birgit Janssen; Joachim Klosterkötter; Wolfgang Maier; Hans-Jürgen Möller; Stephan Ruhrmann; Wolfgang Gaebel
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

5.  Obstructive Sleep Apnea Is Treatable With Continuous Positive Airway Pressure in People With Schizophrenia and Other Psychotic Disorders.

Authors:  Jamilla J Giles; Ivan Ling; Nigel McArdle; Romola S Bucks; Gemma Cadby; Bhajan Singh; Vera A Morgan; Laura Gabriel; Flavie Waters
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 7.348

6.  Lipid Biomarkers in Depression: Does Antidepressant Therapy Have an Impact?

Authors:  Fidelis Christin Stuchtey; Andrea Block; Francis Osei; Pia-Maria Wippert
Journal:  Healthcare (Basel)       Date:  2022-02-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.